Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients

NCT04631211 is registered in ClinicalTrials.gov with Cellphire Therapeutics, Inc. as lead sponsor.

NCT NCT04631211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Lead sponsor
Cellphire Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 5, 2021
Completion date
January 7, 2022
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow aplasia, hematologic malignancy, myelodysplastic syndromes, myeloproliferative disorders, platelet refractoriness, thrombocytopenia